A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis

NCT03798366 | Completed Phase 2 Results DMC FDA Drug

• 2 other identifiers: GLPG1690-CL-2042018-001817-33
• Study Type: interventional
• Target: 33
• Locations: 6 countries
• Sites: 18

Brief Summary

The main purpose of the study is to see if GLPG1690 helps (together with the standard of care treatment) in the treatment of the skin and other areas affected by systemic sclerosis. Another aim is to find out how safe/well tolerated GLPG1690 will be and whether there are any side effects. The study will also look at other things, including whether the study drug affects disease progression and also if it changes any aspect of the quality of life.

Conditions

Systemic Sclerosis

Outcome Measures

Primary Outcomes (4)

• Change From Baseline in mRSS at Week 4

  The mRSS is a validated physical examination method for estimating skin thickness. The 17 body site mRSS was used, with each body site assessed on a scale of 0 (uninvolved) to 3 (severe thickening) with a total score range from 0 (best) to 51 (worst), with higher scores indicating greater severity of skin thickening.

  Baseline, Week 4

• Change From Baseline in mRSS at Week 8

  The mRSS is a validated physical examination method for estimating skin thickness. The 17 body site mRSS was used, with each body site assessed on a scale of 0 (uninvolved) to 3 (severe thickening) with a total score range from 0 (best) to 51 (worst), with higher scores indicating greater severity of skin thickening.

  Baseline, Week 8

• Change From Baseline in mRSS at Week 16

  The mRSS is a validated physical examination method for estimating skin thickness. The 17 body site mRSS was used, with each body site assessed on a scale of 0 (uninvolved) to 3 (severe thickening) with a total score range from 0 (best) to 51 (worst), with higher scores indicating greater severity of skin thickening.

  Baseline, Week 16

• Change From Baseline in mRSS at Week 24

  The mRSS is a validated physical examination method for estimating skin thickness. The 17 body site mRSS was used, with each body site assessed on a scale of 0 (uninvolved) to 3 (severe thickening) with a total score range from 0 (best) to 51 (worst), with higher scores indicating greater severity of skin thickening.

  Baseline, Week 24

Secondary Outcomes (1)

• Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

  Baseline up to end of the study (36 weeks)

Study Arms (2)

GLPG1690 600 mg

EXPERIMENTAL

Participants received GLPG1690 600 milligrams (mg), orally once daily for 24 weeks.

Drug: GLPG1690

Placebo

PLACEBO COMPARATOR

Participants received GLPG1690 matching placebo, orally once daily for 24 weeks.

Drug: Placebo

Interventions

GLPG1690 DRUG

Film-coated tablets of GLPG1690 for oral use.

GLPG1690 600 mg

Placebo DRUG

Film-coated tablets of GLPG1690 matching placebo for oral use.

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able and willing to comply with the protocol requirements and to sign the informed consent form (ICF) as approved by the Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to any screening evaluations.
• Male and female participants ≥18 years at the time of consent who meet the American College of Rheumatology (ACR)/EULAR 2013 diagnostic criteria for systemic sclerosis with diffuse cutaneous involvement (according to LeRoy's criteria) and ≤5 years since the onset of the first systemic sclerosis manifestation other than Raynaud's phenomenon.
• Modified Rodnan Skin Score (mRSS) \>10 at screening.
• Active disease at screening, as defined by: Worsening of skin thickening (≥2 mRSS points) as assessed by mRSS measured at screening versus a previous mRSS assessment made within 6 months prior to screening, or new areas of skin involvement within 6 months prior to screening as documented by physician note, or new-onset systemic sclerosis with symptoms or signs other than Raynaud's phenomenon within 2 years prior to screening, or ≥1 tendon friction rub (palpated in the finger flexors or extensors, wrist flexors or extensors, olecranon bursa, shoulders, knees, anterior or posterior ankles with active motion).
• Participant must be able and willing to comply with restrictions on prior and concomitant medication as described in the protocol
• Female participants of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at the baseline visit.
• Female participants of childbearing potential or male participants with female partners of childbearing potential must be willing to comply with the contraceptive methods described in the protocol prior to the first dose of the investigational medicinal product (IMP), during the clinical study, and for at least 90 days after the last dose of the IMP for male participants and 30 days after the last dose of the IMP for female participants.
• A body mass index (BMI) between 18-35 kg/m\^2, inclusive, at screening.
• Judged to be in good health by the investigator based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and fasting clinical laboratory safety tests. Clinical laboratory safety test results must be within the reference ranges or test results that are outside the reference ranges need to be considered non-clinically significant in the opinion of the investigator.

You may not qualify if:

• Known hypersensitivity to IMP ingredients or history of a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
• Breastfeeding female or participant intending to become pregnant or breastfeed.
• History of or a current immunosuppressive condition (e.g. human immunodeficiency virus \[HIV\] infection, congenital, acquired).
• Positive blood testing for hepatitis B surface antigen or hepatitis C virus (antibody, confirmed by hepatitis C virus ribonucleic acid \[RNA\] positivity). Note: Participants with a resolved hepatitis A at least 3 months prior to screening can be screened.
• History of malignancy within the past 5 years (except for carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin that has been treated with no evidence of recurrence, prostate cancer medically managed through active surveillance or watchful waiting, and squamous cell carcinoma of the skin if fully resected and ductal carcinoma in situ).
• Clinically significant abnormalities, in the opinion of the investigator, detected on ECG at screening of either rhythm or conduction, QT interval corrected for heart rate using Fridericia's formula (QTcF) \>450 ms, or a known long QT syndrome.
• Unstable cardiovascular, pulmonary, or other disease (other than systemic sclerosis-related), in the opinion of the investigator, within 6 months prior to the baseline visit (e.g. coronary heart disease, heart failure, stroke).
• Severe pulmonary disease with forced vital capacity (FVC) ≤45% of predicted within 6 months prior to the baseline visit.
• Chronic or ongoing active infectious disease, including tuberculosis (requiring hospitalization or systemic treatment within 4 weeks prior to the baseline visit).
• Abnormal liver function test (LFT) at screening, defined as aspartate aminotransferase (AST), and/or alanine aminotransferase (ALT), and/or bilirubin, and/or alkaline phosphatase \>2x upper limit of normal (ULN). Retesting is allowed once.

Sponsors & Collaborators

• Galapagos NV: lead

Study Sites (18)

Pacific Arthritis Care Center

Los Angeles, California, 90045, United States

Location

UCLA Rheumatology

Los Angeles, California, 90095, United States

Location

RASF Clinical Research Center

Boca Raton, Florida, 33486, United States

Location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

Metroplex Clinical Research Center

Dallas, Texas, 75231, United States

Location

UT Physicians Center for Autoimmunity

Houston, Texas, 77030, United States

Location

UZ Gent

Ghent, 9000, Belgium

Location

UZ Leuven

Leuven, 3000, Belgium

Location

Charité - Universitätsmedizin Berlin

Berlin, 10117, Germany

Location

Universitätsklinikum Frankfurt

Frankfurt, 60590, Germany

Location

Azienda Ospedaliero

Florence, 50439, Italy

Location

Ospedale San Raffaele S.r.l. - PPDS

Milan, 20132, Italy

Location

Hospital Universitario Vall d'Hebron - PPDS

Barcelona, Spain

Location

Hospital Universitario 12 de Octubre

Madrid, Spain

Location

Hospital Nuestra Señora de Valme

Seville, Spain

Location

University Hospital Aintree

Liverpool, L9 7AL, United Kingdom

Location

Royal Free Hospital

London, NW32QG, United Kingdom

Location

MeSH Terms

Conditions

Scleroderma, Systemic

Interventions

GLPG1690

Condition Hierarchy (Ancestors)

Connective Tissue Diseases; Skin and Connective Tissue Diseases; Skin Diseases

Limitations and Caveats

This was a proof-of-concept study not sized or powered to confirm any treatment effect.

Results Point of Contact

• Title: Galapagos Medical Information
• Organization: Galapagos NV

medicalinfo@glpg.com

+32 15 342 900

Study Officials

• Galapagos Study Director

  Galapagos NV

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 3, 2019
• First Posted: January 9, 2019
• Study Start: January 14, 2019
• Primary Completion: May 21, 2020
• Study Completion: June 22, 2020
• Last Updated: May 4, 2021
• Results First Posted: May 4, 2021

Record last verified: 2021-04

Locations

US (7); BE (2); IT (2); DE (2); ES (3); GB (2)